Physician profile
Sheldon Fleishman
NPI 1245234640
$3,879.43
in general payments reported to CMS, 2019-2025
22 companies · $21.77 in 2025
The $21.77 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $44.06 · 2021: $917 · 2022: $521 · 2023: $992 · 2024: $1,115 · 2025: $21.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,235 · Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,234.84 |
| Food and Beverage | $893.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $1,602.70 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Treace Medical Concepts, INC. | $503.74 | 2021-2023 | |
| Tenex Health INC. | $232.57 | 2021 | |
| Organogenesis INC. | $217.77 | 2019-2022 | |
| Abbvie INC. | $205.69 | 2021-2024 | |
| Nevro Corp. | $193.06 | 2021-2023 | Senza |
| Smith+Nephew, INC. | $168.83 | 2019-2021 | |
| Averitas Pharma INC. | $166.94 | 2023-2024 | Qutenza |
| Baudax Bio INC. | $124.76 | 2021 | |
| Kci USA, INC. | $85.95 | 2022 | |
| Stryker Corporation | $84.50 | 2020-2022 | |
| Next Science LLC | $45.80 | 2023 | Xperience, Surgx, Blastx |
| Wright Medical Technology, INC. | $44.42 | 2019 | |
| Integra Lifesciences Corporation | $34.51 | 2019-2023 | Tenoglide |
| Convatec INC. | $34.15 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $26.87 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.55 | 2022-2023 | Seglentis |
| Polynovo North America LLC | $24.62 | 2022 | |
| Horizon Therapeutics Plc | $20.40 | 2021 | |
| Linvatec Corporation | $13.18 | 2022 | |
| Paratek Pharmaceuticals, INC. | $11.93 | 2021 | |
| Allergan, INC. | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheldon Fleishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.